Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glucagon-like peptide-2(3-33) is a 31-amino acid peptide metabolite of the intestinotrophic hormone glucagon-like peptide-2 (GLP-2). It is generated endogenously through the proteolytic cleavage of the first two N-terminal amino acids (Histidine and Alanine) of GLP-2(1-33) by the enzyme dipeptidyl peptidase-4 (DPP-4). Unlike the intact hormone, which promotes intestinal mucosal growth and nutrient absorption, GLP-2(3-33) acts primarily as a competitive antagonist at the glucagon-like peptide 2 receptor (GLP2R). In some contexts, it has been observed to display weak partial agonist activity, but its predominant physiological and pharmacological role is the inhibition of GLP-2-mediated signaling. It is extensively utilized as a research tool to investigate the biological actions of the GLP-2 system in gut physiology and diseases such as short bowel syndrome and inflammatory bowel disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on glucagon-like peptide-2(3-33).